Loading clinical trials...
Loading clinical trials...
A Verification Study of JNS020QD in Patients With Osteoarthritis or Low Back Pain
The purpose of this study is to evaluate efficacy and safety of fentanyl in opioid-naive participants with osteoarthritis (disorder, which is seen mostly in older persons, in which the joints become painful and stuff) or low back pain who cannot obtain a sufficient analgesic effect by the treatment of non-opioid analgesics (drug used to control pain).
This is a multi-center (conducted in more than one center), double-blind (neither the participant nor the physician knows the assigned study drug), randomized (participants assigned study drug by chance), withdrawal study in opioid-naive participants with osteoarthritis or low back pain. The study will consist of titration period (10-29 days) and double-blind period (12 weeks) and the visits will include Day 5-7, 8, 15, 29 in titration period and Day 2-4, 8, 15, 22, 29, 43, 57, 71 and 85 in double-blind period. All the eligible participants will receive one-day adhesive transdermal patch (patch containing a drug that is put on the skin so the drug will enter the body through the skin) of either fentanyl at the dose ranging from 12.5 to 50 microgram per hour (mcg/hr) or matching placebo. Efficacy will be evaluated primarily by time to withdrawal due to insufficient analgesic efficacy. Participants' safety will be monitored throughout the study.
Age
20 - No limit years
Sex
ALL
Healthy Volunteers
No
Aki, Japan
Akō, Japan
Amagasaki, Japan
Anan, Japan
Annaka, Japan
Chiba, Japan
Chiisagata, Japan
Fuchū, Japan
Fukuoka, Japan
Fukuyama, Japan
Start Date
January 1, 2009
Primary Completion Date
February 1, 2010
Completion Date
February 1, 2010
Last Updated
December 25, 2013
218
ACTUAL participants
Fentanyl
DRUG
Placebo
DRUG
Lead Sponsor
Janssen Pharmaceutical K.K.
NCT07153471
NCT07351968
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06381791